Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

James Nathan Gerson, MD, Stefan Klaus Barta, MDMRCP,MS, Diego Villa, Alina S Gerrie, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, Michael Wang, MD, Brian T. Hill, MD PhD, Yazeed Sawalha, MD, Francisco J. Hernandez-Ilizaliturri, MD, Shalin Kothari, MD, Julie M Vose, MD, Timothy S. Fenske, MD, Swapna Narayana Rao, MD, Kami J. Maddocks, MD, David A Bond, MD, Frederick Lansigan, MD, Timothy Burns, MD, Alexandra M Donovan, MD, Amitkumar Mehta, MD, Nishitha Reddy, MD MSCI, MBBS, Daniel J. Landsburg, MD, Martha Glenn, MD, David James Inwards, MD, Kay Ristow, Reem Karmali, MD MS, Jason Kaplan, MD, Elvira Umyarova, MD, Bhargavi Pulluri, MD, Jennifer E Amengual, MD, Jennifer Kimberly Lue, MD, Paolo Caimi, MD, Jonathon B Cohen, MDMS, Oscar Calzada, BS, Elizabeth Handorf, Jennifer Kelly Anderson, MD, Parv Chapani, Veronika Bachanova, MD PhD, Saurabh Rajguru, MD, Michael C Churnetski, BS, Catherine Diefenbach, Martin Bast, Alexandra E. Kovach, MD

Blood (2017) 130 (Supplement 1): 341.

https://doi.org/10.1182/blood.V130.Suppl_1.341.341

Published: 2017

Journal Articles

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Manzurul A. Sikder, MD, Sughosh Dhakal, Jennifer Kelly, MPH, Steven H. Bernstein, MD, Faith Young, MD, Richard I. Fisher, MD, Jonathan Friedberg, MD, Louis Constine, MD

Blood (2007) 110 (11): 3433.

https://doi.org/10.1182/blood.V110.11.3433.3433

Published: 2007

Journal Articles

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).

Jonathan W. Friedberg, Jennifer Kelly, Susan Voci, Diana Marquis, Lynn Rich, Randall Rossi, Steven Bernstein, Craig Jordan, Jane Liesveld, Richard I. Fisher

Blood (2007) 110 (11): 2325.

https://doi.org/10.1182/blood.V110.11.2325.2325

Published: 2007

Journal Articles

Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era.

Jonathan W. Friedberg, Elizabeth Sensenig, Jennifer Kelly, Jamie Oliva, Louis Constine, Michael Becker, Gordon Phillips, Jane Liesveld, Richard I. Fisher, Steven H. Bernstein

Blood (2007) 110 (11): 1907.

https://doi.org/10.1182/blood.V110.11.1907.1907

Published: 2007

Journal Articles

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

James N. Lowder, MD, Jonathan W. Freidberg, MD, Jennifer Kelly, Arnold S. Freedman, MD, Robert Coffman, PhD, Holger Kanzler, PhD, Paul Sims, Jimmy Hwang, MD, Nicholas Haining

Blood (2007) 110 (11): 3844.

https://doi.org/10.1182/blood.V110.11.3844.3844

Published: 2007

Journal Articles

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Jonathan W. Friedberg, MD, MMSc, Jennifer Kelly, MPH, Jeffrey L. Kutok, MD, Rabih Salloum, MD, David C. Fisher, MD, Elizabeth Ronan, Virginia Dalton, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, MD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2006) 108 (11): 2713.

https://doi.org/10.1182/blood.V108.11.2713.2713

Published: 2006

Journal Articles

Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.

Jonathan W. Friedberg, MD, Lauren Ciminello, Jennifer Kelly, Simon Clawson, MD, Dieter Hoelzer, MD, Harald Holte, MD, Ann S. LaCasce, MD, Graham Mead, MD, Deborah Thomas, MD, Gustaaf W. van Imhoff, MD, Bruce Cheson, MD, Ian T. Magrath, MB, Richard I. Fisher, MD

Blood (2005) 106 (11): 928.

https://doi.org/10.1182/blood.V106.11.928.928

Published: 2005

Journal Articles

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Jonathan W. Friedberg, MD, Jennifer Kelly, Jeffrey L. Kutok, MD, Rabih Salloum, MD, Thomas Brenn, MD, David C. Fisher, MD, Elizabeth Ronan, Mary McCauley, RN, Lynn Rich, RN, Diana Marquis, Paul G. Rothberg, PhD, Jane Liesveld, MD, Richard I. Fisher, MD, Robert Coffman, PhD, Tim Mosmann, PhD, Arnold S. Freedman, MD

Blood (2005) 106 (11): 2434.

https://doi.org/10.1182/blood.V106.11.2434.2434

Published: 2005

NARROW

Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL).

Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era.

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

Outcome of Patients > Age 40 with Burkitt Lymphoma (BL) Treated with Aggressive Chemotherapuetic Regimens: Results from the International Burkitt Lymphoma Collaborative Group.

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only